


Proving the efficacy of local treatment in liver cancer oligometastases

November 2 2023



The inclusion process. Credit: *Cancers* (2023). DOI: 10.3390/cancers15133467

Professor Chai Hong Rim of the Department of Radiation Oncology, Korea University's Ansan Hospital, along with student Jungsue Lee and Sooyeon Kim of the College of Medicine, Korea University, proved the efficacy of active local treatment such as radiotherapy and radiofrequency ablation (RFA) in liver cancer oligometastases (less than 3 to 5 metastatic foci) through a meta-analysis study.

Liver [cancer](#) is being called as a "silent killer" and is a cancer that is very difficult to detect early, because there are no clear symptoms in the early stages. According to the statistics of National Cancer Information Center, [liver cancer](#) has a [poor prognosis](#), ranking the [second place](#) (12.4%) among causes of cancer death. The life expectancy is known to be less than 3 to 6 months when only [conservative treatment](#) is performed on metastatic liver cancer.

Although the use of anticancer drugs is generally considered first in the treatment of metastatic cancer, its role had been limited in the treatment of metastatic liver cancer. Not only that, in some cases, active treatment for liver cancer is withdrawn because the role of local treatment, such as radiotherapy and RFA for metastatic lesions has not been sufficiently studied.

Professor Chai Hong Rim's research team performed a systematic literature analysis based on a total of 527 liver cancer oligometastatic patients' data in order to identify the efficacy of local treatment in liver cancer oligometastases.

The analysis showed that the group underwent local treatment, such as radiotherapy and RFA, had significantly improved survival rate

compared to the group that did not (Odds Ratio: 4.664, p

Citation: Proving the efficacy of local treatment in liver cancer oligometastases (2023, November 2) retrieved 21 May 2024 from <https://medicalxpress.com/news/2023-11-efficacy-local-treatment-liver-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.